24/7 Market News Snapshot 22 September, 2025 – Imunon, Inc. Common Stock (NASDAQ:IMNN)

September 22, 2025

DENVER, Colo., 22 September, 2025 (www.247marketnews.com) – (Nasdaq:IMNN) are discussed in this article.
IMUNON, Inc. (Nasdaq:IMNN) is experiencing an upward trend in the pre-market session, trading at $5.136, which signifies a gain of approximately 3.13% from its previous close of $4.980. This positive momentum is reflected in a substantial trading volume of 729.15K shares, suggesting strong investor interest. Technical analysis indicates that the stock has successfully surpassed recent resistance levels, which may signal further potential for upward movement. Investors are advised to keep an eye on key support levels to optimize their entry points, as the increase in volume alongside price appreciation indicates a robust outlook for the stock in the near term.

In tandem with its stock market performance, IMUNON has announced promising data from its Phase 2 OVATION 2 Study, which emphasizes the efficacy of IMNN-001, an innovative gene-based immunotherapy designed to treat newly diagnosed advanced ovarian cancer. Data from the study were presented at the American Association for Cancer Research (AACR) Special Conference on ovarian cancer. The study, involving 112 participants, highlighted significant changes in the tumor microenvironment, showcasing improved immune responses following treatment with IMNN-001 in conjunction with standard chemotherapy.

Findings reveal a favorable shift in the tumor microenvironment, highlighted by an increase in anti-tumor CD8+ T cells and myeloid dendritic cells, coupled with a reduction in immunosuppressive markers among the majority of participants. Dr. Douglas V. Faller, Chief Medical Officer of IMUNON, expressed optimism regarding the data, indicating that they align with previously reported positive overall survival results. The company is advancing its Phase 3 OVATION 3 trial, actively enrolling participants across multiple sites, with plans to expand site locations in order to enhance patient recruitment. IMUNON continues to leverage its TheraPlas® technology platform in a bid to meet significant unmet needs in cancer therapy, aiming to improve outcomes for patients battling ovarian cancer.

Related news for (IMNN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.